Ebola Virus Net is the web resource for anyone interested in ebola. Ebola (Ebola hemorrhagic fever), is a severe, often fatal disease in humans and nonhuman primates such as monkeys, gorillas, and chimpanzees. Ebola is a rare and deadly disease caused by infection with a virus of the family Filoviridae, genus Ebolavirus. There are five identified Ebolavirus species, four of which have caused disease in humans. Ebola is found in several African countries. The first Ebola species was discovered in 1976 near the Ebola River in the Democratic Republic of the Congo. Since then, outbreaks have appeared sporadically in Africa. The largest outbreak to date was the epidemic in West Africa, which occurred from December 2013, to January 2016, with 28,646 cases and 11,323 deaths. Other outbreaks in Africa began in the Democratic Republic of the Congo in May 2017 and 2018. In July 2019, the World Health Organization declared the Congo Ebola outbreak a world health emergency.

When an infection does occur in humans, the virus can be spread to others through direct contact with the blood or body fluids of a person who is sick with Ebola, or through contact with objects that have been contaminated with the blood or body fluids of an infected person. Until recent, no vaccines were effective. In December 2016, Ebola was found to be 70–100% prevented by rVSV-ZEBOV vaccine, making it the first proven vaccine against the disease. More than 100,000 people have been vaccinated against Ebola as of 2019.

The objectives of Ebola Virus Net are to be the public and professional information resource for ebola and to serve as a network in the exchange of information and news related to ebola.

• Nanobody test detects all known species of Ebola virus - Chemical & Engineering News
  Sat, 22 Jan 2022 00:23 GMT
• Could Liberians' Appetite for Bushmeat Trigger the Next Ebola Outbreak? - Liberian Daily Observer
  Fri, 21 Jan 2022 00:39 GMT
• The family tragedy that drives Queensland's no-nonsense top - Daily Mail
  Fri, 21 Jan 2022 13:05 GMT
• Why bats? The common secret behind COVID and Ebola - Nikkei Asia
  Fri, 31 Dec 2021 08:00 GMT
• Ebola Virus Vaccine Market Research Growth by Manufacturers, Regions, Type and Application, Forecast Analysis to 2029 – The Oxford Spokesman - The Oxford Spokesman
  Sun, 23 Jan 2022 23:11 GMT
• Ebola virus disease – Democratic Republic of the Congo - World Health Organization
  Sun, 10 Oct 2021 07:00 GMT
• Ebola outbreak in DRC’s east declared over - Al Jazeera English
  Thu, 16 Dec 2021 08:00 GMT
• We now know a major cause of multiple sclerosis. Can we eradicate it? - World Economic Forum
  Fri, 21 Jan 2022 13:02 GMT
• Several deaths in DRC prompt concerns of another Ebola outbreak - Healio
  Mon, 11 Oct 2021 07:00 GMT
• Sherif Ramzy Zaki - The Lancet
  Sat, 22 Jan 2022 08:00 GMT
• Ivory Coast detects first Ebola case in 25 years - Reuters
  Sun, 15 Aug 2021 07:00 GMT
• Ebola virus can lie low and reactivate after years in human survivors - Nature.com
  Wed, 15 Sep 2021 07:00 GMT
• Ebola resurfaced: some viruses are never really gone - Cosmos Magazine
  Mon, 04 Oct 2021 07:00 GMT
• WHO declares end to second Ebola outbreak in Guinea - Al Jazeera English
  Sat, 19 Jun 2021 07:00 GMT
• Bill & Melinda Gates Foundation and Wellcome Pledge US$300 Million to CEPI for COVID-19 Pandemic Response and to Accelerate Epidemic Preparedness - World - ReliefWeb
  Wed, 19 Jan 2022 06:58 GMT

• PRO/AH/EDR> Ebola update (44): Burkina Faso ex Cote d'Ivoire, 2nd case, NOT
  Mon, 30 Aug 2021 11:01:25 -0400
  Ebola -- Burkina Faso
  On 22 Aug 2021, the Ministry of Health informed the population of the admission to the Medical Emergencies of the Bogodogo University Hospital (CHU-B) of a 22-year-old patient who had stayed in the Republic of [Cote d'Ivoire]. The diagnostic procedure consisted of sampling analysis at the National Reference Laboratory for Viral Haemorrhagic Fever (LNR-FHV at the Muraz Centre) and the Pasteur Institute of Dakar for confirmation. The results obtained make it possible to permanently rule out

• Cynarin blocks Ebola virus replication by counteracting VP35 inhibition of interferon-beta production Sun, 23 Jan 2022 06:00:00 -0500
  Ebola virus (EBOV) is one of the deadliest infective agents whose lethality is linked to the ability to efficiently bypass the host's innate antiviral response. EBOV multifunctional protein VP35 plays a major role in viral replication both as polymerase cofactor and interferon (IFN) antagonist. By hiding the non-self 5'-ppp dsRNA from the cellular receptor RIG-I, VP35 prevents its activation and inhibits IFN-β production. Blocking VP35-dsRNA interaction and IFN-β suppression is a validated drug...
• Ebola Virus GP Activates Endothelial Cells via Host Cytoskeletal Signaling Factors Sat, 22 Jan 2022 06:00:00 -0500
  Ebola virus disease (EVD) is a lethal disease caused by the highly pathogenic Ebola virus (EBOV), and its major symptoms in severe cases include vascular leakage and hemorrhage. These symptoms are caused by abnormal activation and disruption of endothelial cells (ECs) whose mediators include EBOV glycoprotein (GP) without the need for viral replication. However, the detailed molecular mechanisms underlying virus-host interactions remain largely unknown. Here, we show that EBOV-like particles...
• Activity of Galidesivir in a Hamster Model of SARS-CoV-2 Sat, 22 Jan 2022 06:00:00 -0500
  Coronavirus disease 2019 (COVID-19) has claimed the lives of millions of people worldwide since it first emerged. The impact of the COVID-19 pandemic on public health and the global economy has highlighted the medical need for the development of broadly acting interventions against emerging viral threats. Galidesivir is a broad-spectrum antiviral compound with demonstrated in vitro and in vivo efficacy against several RNA viruses of public health concern, including those causing yellow fever,...
• Association between oral antimalarial medication administration and mortality among patients with Ebola virus disease: a multisite cohort study Fri, 21 Jan 2022 06:00:00 -0500
  CONCLUSION: Early oral antimalarial treatment in an EVD outbreak was associated with reduced mortality. Further study is warranted to investigate this association between early oral antimalarial treatment and mortality in EVD patients.
• The ring vaccination trial design for the estimation of vaccine efficacy and effectiveness during infectious disease outbreaks Fri, 21 Jan 2022 06:00:00 -0500
  The ring vaccination trial is a recently developed approach for evaluating the efficacy and effectiveness of vaccines, modeled after the surveillance and containment strategy of ring vaccination. Contacts and contacts of contacts of a newly identified disease case form a ring, and these rings are randomized as part of a cluster-randomized trial or with individual randomization within rings. Key advantages of the design include its flexibility to follow the epidemic as it progresses and the...
• TRIPS to Where? A Narrative Review of the Empirical Literature on Intellectual Property Licensing Models to Promote Global Diffusion of Essential Medicines Fri, 21 Jan 2022 06:00:00 -0500
  Governed through the World Trade Organization Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) since 1995, the current medical R&D system requires significant trade-offs between innovation and high monopoly prices for patented drugs that restrict patient access to medicines. Since its implementation, few amendments have been made to the original TRIPS agreement to allow low- and middle-income countries (LMICs) to facilitate access by generic manufacturers through...
• HIV-1 trans-Infection Mediated by DCs: The Tip of the Iceberg of Cell-to-Cell Viral Transmission Fri, 21 Jan 2022 06:00:00 -0500
  HIV-1 cell-to-cell transmission is key for an effective viral replication that evades immunity. This highly infectious mechanism is orchestrated by different cellular targets that utilize a wide variety of processes to efficiently transfer HIV-1 particles. Dendritic cells (DCs) are the most potent antigen presenting cells that initiate antiviral immune responses, but are also the cells with highest capacity to transfer HIV-1. This mechanism, known as trans-infection, relies on the capacity of...
• Scientometric Analysis of Public Health Emergencies: 1994-2020 Fri, 21 Jan 2022 06:00:00 -0500
  The purpose of this paper is to summarize the research hotspots and frontiers in the field of public health emergencies (PHE) between 1994-2020 through the scientometric analysis method. In total, 2247 literature works retrieved from the Web of Science core database were analyzed by CiteSpace software, and the results were displayed in knowledge mapping. The overall characteristics analysis showed that the number of publications and authors in the field of PHE kept an upward trend during the...
• Synthetic nanobody-functionalized nanoparticles for accelerated development of rapid, accessible detection of viral antigens Thu, 20 Jan 2022 06:00:00 -0500
  Successful control of emerging infectious diseases requires accelerated development of fast, affordable, and accessible assays for wide implementation at a high frequency. This paper presents a design for an in-solution assay pipeline, featuring nanobody-functionalized nanoparticles for rapid, electronic detection (Nano2RED) of Ebola and COVID-19 antigens. Synthetic nanobody binders with high affinity, specificity, and stability are selected from a combinatorial library and site-specifically...
• Synthesis and biological application of glyco- and peptide derivatives of fullerene C₆₀ Thu, 20 Jan 2022 06:00:00 -0500
  Fullerenes have attracted considerable attention for their possible use in human therapy. Pure C(60) is soluble only in some organic solvents, but this could be overcome by chemical modifications. This review investigates the derivatization strategies and biological applications of fullerene C(60) by using polar "active" molecules as sugars and amino acids/peptides that allow the increase of solubility in water. The effect of glycosylation on biological activity of fullerene can be divided in...